Suven Life gets patent for neuro-degenerative related products

Company has secured patents from China and South Africa to the new chemical entities for central nervous system therapy

Drug firm Suven Life Sciences has been granted patents by China, South Africa and Mexico for new chemical molecules that can be used in drugs for treating neuro-degenerative diseases.

Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.

In a BSE filing, the company said that it "secured patents from China and South Africa to the new chemical entities (NCE) for central nervous system (CNS) therapy".

The patents are valid until 2031, 2030 and 2031, respectively, Suven Life Sciences said.

It further said: "Suven also secured a patent for their NCE in Mexico and the granted claims of this patent include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder and the patent is valid through 2030."

Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."

With these, Suven has a total of 16 granted patents from China, 19 from Mexico and 22 from South Africa.

"These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.

"Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II," Suven said.

Shares of Suven Life Sciences soared by 4.61 per cent to Rs 246.35 apiece in morning trade on BSE.